• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 3. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 4. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 5. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088

Introduction to 4-Amino-1-alpha-D-arabinofuranosyl-2(1H)-pyrimidinone (CAS No. 7428-39-9)

4-Amino-1-alpha-D-arabinofuranosyl-2(1H)-pyrimidinone, with the chemical identifier CAS No. 7428-39-9, is a significant compound in the field of pharmaceutical chemistry and biochemistry. This nucleoside derivative has garnered considerable attention due to its structural uniqueness and potential biological activities. The compound belongs to the class of pyrimidine-based molecules, which are fundamental in the synthesis of nucleic acids and have been extensively studied for their therapeutic applications.

The structural framework of 4-Amino-1-alpha-D-arabinofuranosyl-2(1H)-pyrimidinone consists of a pyrimidine core substituted with an amino group at the 4-position and an alpha-D-arabinofuranosyl moiety at the 1-position. This configuration makes it a valuable intermediate in the synthesis of more complex nucleoside analogs, which are widely explored for their antiviral, anticancer, and anti-inflammatory properties. The presence of the amino group enhances its reactivity, allowing for further functionalization and derivatization, which is crucial in drug development pipelines.

In recent years, there has been a surge in research focused on nucleoside analogs due to their ability to mimic natural nucleosides and interfere with essential biological pathways in pathogens. 4-Amino-1-alpha-D-arabinofuranosyl-2(1H)-pyrimidinone has been investigated for its potential role in inhibiting viral replication, particularly in the context of RNA viruses. Studies have shown that modifications at the pyrimidine ring can significantly alter the pharmacokinetic and pharmacodynamic properties of nucleoside analogs, making them more effective against target pathogens.

One of the most compelling aspects of 4-Amino-1-alpha-D-arabinofuranosyl-2(1H)-pyrimidinone is its versatility as a building block for designing novel therapeutic agents. Researchers have leveraged its scaffold to develop derivatives with enhanced binding affinity to viral enzymes such as polymerases and reverse transcriptases. These enzymes are critical for viral replication, and inhibiting them can effectively halt the spread of infections. The compound’s ability to be modified at multiple positions allows chemists to fine-tune its properties, making it a promising candidate for structure-activity relationship (SAR) studies.

The synthesis of 4-Amino-1-alpha-D-arabinofuranosyl-2(1H)-pyrimidinone involves multi-step organic reactions that require precise control over reaction conditions and reagent selection. The alpha-D-arabinofuranosyl moiety is particularly challenging to introduce due to its stereogenic center, necessitating advanced synthetic methodologies such as enzymatic glycosylation or protecting group strategies. Despite these challenges, significant progress has been made in optimizing synthetic routes, making large-scale production feasible for research and commercial purposes.

Recent advancements in computational chemistry have further accelerated the development of nucleoside analogs like 4-Amino-1-alpha-D-arabinofuranosyl-2(1H)-pyrimidinone. Molecular modeling techniques allow researchers to predict the binding interactions between the compound and biological targets with high accuracy. This approach has enabled the rapid design of derivatives with improved efficacy and reduced toxicity. Additionally, high-throughput screening methods have been employed to identify promising candidates from large libraries of nucleoside analogs, streamlining the drug discovery process.

The therapeutic potential of 4-Amino-1-alpha-D-arabinofuranosyl-2(1H)-pyrimidinone extends beyond antiviral applications. Preliminary studies suggest that it may exhibit anticancer properties by inhibiting key enzymes involved in DNA replication and repair in tumor cells. The ability of nucleoside analogs to selectively target rapidly dividing cells makes them attractive candidates for cancer therapy. Further research is needed to fully elucidate these mechanisms and explore potential clinical applications.

Another area of interest is the use of 4-Amino-1-alpha-D-arabinofuranosyl-2(1H)-pyrimidinone as a prodrug or pharmacophore carrier. By incorporating this scaffold into larger molecules, researchers can enhance drug delivery systems or improve bioavailability. The compound’s unique structural features make it an excellent candidate for designing prodrugs that release active pharmaceutical ingredients (APIs) under specific physiological conditions, thereby improving therapeutic outcomes.

The safety profile of 4-Amino-1-alpha-D-arabinofuranosyl-2(1H)-pyrimidinone is another critical consideration in its development as a therapeutic agent. While initial studies suggest that it exhibits moderate toxicity at high doses, further research is needed to assess its long-term effects and potential side effects. Pharmacokinetic studies are essential to understand how the compound is metabolized and excreted by the body, which will inform dosing regimens and minimize adverse reactions.

In conclusion, 4-Amino-1-alpha-D-arabinofuranosyl-2(1H)-pyrimidinone (CAS No. 7428-39-9) represents a promising compound in pharmaceutical chemistry with diverse applications ranging from antiviral therapy to cancer treatment. Its unique structural features and reactivity make it an invaluable intermediate for developing novel therapeutic agents. As research continues to uncover new biological functions and synthetic methodologies, the potential uses of this compound are expected to expand further, contributing significantly to advancements in medicine.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)